MEDP vs TMO
MEDP: Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | MEDP | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $577.11 | $559.53 | |
| Market cap as of 2026-08-02 | $16.5B | $206.9B | |
| P/E as of 2026-08-02 | 33.85 | 30.64 | TMO lower |
| PEG as of 2026-08-02 | 2.73 | 3.39 | MEDP lower |
| Net margin as of 2026-08-02 | +17.7% | +15.0% | MEDP higher |
| Gross margin as of 2026-08-02 | +28.8% | +40.9% | TMO higher |
| Operating margin as of 2026-08-02 | +21.0% | +17.6% | MEDP higher |
| ROE as of 2026-08-02 | +110.1% | +13.3% | MEDP higher |
| ROA as of 2026-08-02 | +24.8% | +6.3% | MEDP higher |
| Debt / equity as of 2026-08-02 | 0.00 | 0.81 | MEDP lower |
| Revenue growth (YoY) as of 2026-08-02 | +24.7% | +7.2% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +20.1% | -0.3% | MEDP higher |
| Dividend yield as of 2026-08-02 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-02 | 0.96 | 0.85 | |
| 1-year return as of 2026-07-31 close | +35.1% | +17.0% | MEDP higher |
Fundamentals: market data, as of 2026-08-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.